Stockscreener 앱 받기
1.15
1.71%
-0.02
시간 외 거래:
1.15
Boundless Bio Inc 주식(BOLD)의 최신 뉴스
Risks Report: Is Boundless Bio Inc stock a smart retirement pick2026 Price Momentum & Technical Confirmation Trade Alerts - baoquankhu1.vn
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 - The Manila Times
Inside a novel cancer drug aiming at ecDNA-positive, high-risk breast tumors - Stock Titan
Bear Alert: Can Boundless Bio Inc ride the EV waveInsider Buying & Weekly Momentum Picks - baoquankhu1.vn
Trend Review: Can Boundless Bio Inc maintain its current growth rateWeekly Trade Recap & Weekly High Return Stock Opportunities - baoquankhu1.vn
FORTY Should I Buy - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Gains Report: What are the analyst revisions for Boundless Bio IncIs RAAQU stock a good investment in YEARWeekly Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
ASTI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Boundless Bio posts smaller-than-expected Q4 loss - MSN
CVU Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AHRT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Leerink reiterates Market Perform on Boundless Bio stock at $4 - Investing.com
Boundless Bio Reports Q4 and Full Year 2025 Financial Results, Highlights Progress of KOMODO-1 Clinical Trial and BBI-940 Program - Minichart
03268 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
02400 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MGRD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Boundless Bio (BOLD) Posts First Revenue of $17.3M, Narrows Q4 Loss to $0.58/Share - AlphaStreet
Bold Biosciences 2025 10-K: ecDNA-Enabled Cancer Drug Development, Spyglass Platform & BBI-940 Kinesin Degrader Overview - Minichart
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Bitget
Boundless Bio beats fourth quarter loss estimates By Investing.com - Investing.com Canada
Boundless Bio 10-K: $0 Revenue, $(58.2)M Net Loss, $(63.6)M Operating Loss - TradingView
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewswire Inc.
Boundless Bio (Nasdaq: BOLD) trims 2025 loss, funds KOMODO-1 into 2028 - Stock Titan
Exit Recap: Is Boundless Bio Inc stock a smart retirement pickEarnings Summary Report & AI Enhanced Trading Signals - baoquankhu1.vn
Breakouts Watch: Can MSPRI sustain its profitabilityMarket Performance Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
Boundless Bio to Participate in the Leerink Global Healthcare Conference - The Manila Times
Rezolute to Participate in the Citizens Life Sciences Conference - Bitget
Boundless Bio CEO to join Leerink healthcare fireside chat on March 11 - Stock Titan
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight – Company AnnouncementFT.com - Financial Times
BOLD Should I Buy - Intellectia AI
BOLD SEC FilingsBOUNDLESS BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
MDCX PE Ratio & Valuation, Is MDCX Overvalued - Intellectia AI
Signal Recap: How liquid is AMBIWS stock2025 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Volume Recap: Can Broadstone Net Lease Inc outperform under higher oil prices2025 Geopolitical Influence & Weekly Setup with High ROI Potential - baoquankhu1.vn
Nextech exits Boundless Bio (NASDAQ: BOLD) with reported 0% ownership - Stock Titan
Will Boundless Bio Inc. stock continue dividend increasesInflation Watch & Consistent Income Trade Recommendations - mfd.ru
What Makes CTS (CTS) a New Buy Stock - Bitget
What Makes KB Financial (KB) a Strong Momentum Stock: Buy Now? - Bitget
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why - Yahoo Finance
Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial - TipRanks
FMR LLC Reduces Stake in Boundless Bio Inc: A Strategic Portfoli - GuruFocus
What is the long term forecast for Boundless Bio Inc. stockJuly 2025 Analyst Calls & Weekly High Conviction Ideas - mfd.ru
Investment Recap: What are the analyst revisions for Boundless Bio IncIs RAAQU stock a good investment in YEARJuly 2025 Chart Watch & Fast Exit Strategy with Risk Control - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Fed Watch: Does Boundless Bio Inc have pricing powerWall Street Watch & Momentum Based Trading Signals - baoquankhu1.vn
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Fund Flows: Can Boundless Bio Inc weather a recession2025 Investor Takeaways & AI Forecast Swing Trade Picks - baoquankhu1.vn
Boundless Bio CEO Zachary Hornby to Speak at Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Cancer biotech Boundless Bio preps Guggenheim fireside chat with online webcast - Stock Titan
Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth? - simplywall.st
Patterns Watch: Is Boundless Bio Inc subject to activist investor interestQuarterly Trade Review & Risk Managed Investment Strategies - baoquankhu1.vn
We're Keeping An Eye On Boundless Bio's (NASDAQ:BOLD) Cash Burn Rate - Yahoo Finance
Layoff Tracker: Gilead Continues California Cuts With 34 Laid Off - BioSpace
Is Boundless Bio Inc. stock a good pick for beginnersJuly 2025 Short Interest & AI Driven Price Predictions - mfd.ru
1.20%
0.06%
자본화:
|
볼륨(24시간):